Wyzerr, a member of Station Houston's Ion Smart Cities Accelerator, has a way to better collect information from citizens. Photo courtesy of Wyzerr

In a 2019 report card handed out by Cincinnati-based startup Wyzerr, Houston didn't do too well — It got a C, a 2.5 out of 4. Houston is passing, but just barely.

Wyzerr didn't give the city a bad rating; Houstonians did. In July, Wyzerr sent two researchers downtown to hang out near public places — bus stops, street corners, etc. Overall, respondents said they are satisfied with dining options, shopping, and the airports but were really struggling to embrace long commutes, poor local transit, and even public services: the police department, local government, schools and parking all got grades of C minus.

Wyzerr, which has ventured to Houston to partake in the ongoing Ion Smart Cities Accelerator out of Station Houston, is focused on creating surveys that make it easier for companies — and, increasingly, cities and airports — to collect useful information to improve their offerings.

"You can't build perfect cities," says Natasia Malaihollo, founder of Wyzerr. "But if you make small, incremental improvements, you can start to see a difference in communities (through Wyzerr's smart surveys)."

Wyzerr began in June 2014 and focused on designing smart survey for retailers. Now, the company works with more than 2,100 small and large businesses, including Kroger, Walmart, Facebook, Unilever — a lot of consumer packaged goods, Malaihollo says.

Wyzerr is focused on creating engaging surveys to better collect information. Photo courtesy of Wyzerr

Consumers interact with many of these brands on a near-daily basis, and Malaihollo estimates a person might get his with 7 surveys in a day — some of which require dialing in, or going online, or filling out responses on a sheet of receipt paper.

But Wyzerr makes surveys fun — they're interactive and game-like. Most importantly, though, they're short. Nearly every survey is designed to wind a customer through 25 questions about their experience with a certain retailer, product or service in 30 to 60 seconds. There's a science to it — shorter word counts on survey questions, for example, and making the final questions as engaging as possible, because people usually start answering more quickly, and maybe less thoughtfully, toward the end of a survey form.

Malaihollo calls this a design-focused approach to market research, and it has gotten results. In some surveys, Wyzerr was able to gather data on up to 20 percent of total consumers. Unlike most survey engagement, which usually falls lower, Wyzerr's data meets the threshold for statistical analysis — a valid sample size, in mathematics, is 10 percent of the population.

Two years ago, the Cincinnati Airport approached them. Amid a stream of reports that airports would develop into great hubs for the future of retail, the Cincinnati Airport team wanted a way to track shoppers' satisfaction as they trafficked through the terminals. Wyzerr created a survey that connected to the airport's Wi-Fi system — if users wanted to log on, they had to take a brief survey first.

"That ended up being our most successful campaign," Malaihollo says.

Wyzer, which has a team of 12, has raised $2 million and is getting ready to raise more. Upon completion of the accelerator program, the company will work with a Houston neighborhood for a pilot program, and the team hopes to get their survey system on the Wi-Fi system in Houston airports early next year.

Now, Wyzerr focuses on gathering data for smart cities — urban spaces that offer higher-tech solutions to regular city activities, like parking, and use electronic sensors to collect data that helps monitor the public. For example, cities across the U.S. have adapted free Wi-Fi on public transit, parking lot trackers, smart traffic lights to reduce congestion, automated bike-sharing programs and pedestrian detectors at intersections.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.